EUVIMEDEUVIMED entdecken
Crossref

Rifampicin drug monitoring in TB patients: new evidence for increased dosage?

M Schiuma, M Colaneri, D Cattaneo, M Fusi, A Civati, M Galimberti, M V Cossu, C Gervasoni, A Dolci, A Riva, S Antinori, A Gori und 1 weitere

The International Journal of Tuberculosis and Lung Disease · 2025

DOI: 10.5588/ijtld.24.0465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2025. Verfasst von M Schiuma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Rifampin, Drug Monitoring, Tuberculosis, Antibiotics, Antitubercular. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

The standard 10 mg/kg rifampicin (RIF) dose for TB treatment may be insufficient. Higher doses improve microbiological efficacy without increasing adverse effects. Therapeutic drug monitoring (TDM) may help to optimise RIF dosing by measuring 2, 4, and 6 h post-dose concentrations (C2, C4, C6) and area under the curve (AUC).





METHODS

This retrospective study included TB patients receiving RIF 10 mg/kg. TDM assessed C2, peak concentrations (C max ), AUC and timing of C max . Patients achieving target C max (>8 mg/L) and AUC (>67.5 mg*h/L) were evaluated, and dosages were adjusted accordingly. Differences in AUC between TB disease and infection, as well as between diabetic and non-diabetic patients, were evaluated. Side effects were recorded.





RESULTS

Among 181 patients, the median AUC was 57.9 mg*h/L. While 69.6% reached a C max >8 mg/L, only 40.9% met the target AUC. Delayed C max (at 4 or 6 h) occurred in 24.8% of patients. RIF doses were increased to a median of 14.1 mg/kg in 49.2% of patients, with no adverse events. After a follow-up of a median of 12 months, no new occurrence of TB disease was recorded.





CONCLUSION

AUC-based TDM revealed suboptimal RIF exposure in many TB patients at standard doses, suggesting that higher doses are needed to improve treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinDrug MonitoringTuberculosisAntibiotics, AntitubercularAntitubercular AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedAdultArea Under CurveDose-Response Relationship, DrugAgedYoung Adult

Substanzen

RifampinAntibiotics, AntitubercularAntitubercular Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
  • Department of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy.
  • Unit of Clinical Pathology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
  • Department of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy;, Unit of Clinical Pathology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
  • Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy;, Department of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy.
  • Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy;, Department of Biomedical and Clinical Sciences, Università degli studi di Milano, Milan, Italy;, Centre for Multidisci…

Zitieren

APA

Schiuma, M., Colaneri, M., Cattaneo, D., Fusi, M., Civati, A., Galimberti, M., Cossu, M. V., Gervasoni, C., Dolci, A., Riva, A., Antinori, S., Gori, A., & Torre, A. (2025). Rifampicin drug monitoring in TB patients: new evidence for increased dosage?. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.24.0465

Vancouver

Schiuma M, Colaneri M, Cattaneo D, Fusi M, Civati A, Galimberti M, et al. Rifampicin drug monitoring in TB patients: new evidence for increased dosage?. The International Journal of Tuberculosis and Lung Disease. 2025. doi:10.5588/ijtld.24.0465

BibTeX
@article{Schiuma2025,
  author = {Schiuma, M and Colaneri, M and Cattaneo, D and Fusi, M and Civati, A and Galimberti, M and Cossu, M V and Gervasoni, C and Dolci, A and Riva, A and Antinori, S and Gori, A and Torre, A},
  title = {Rifampicin drug monitoring in TB patients: new evidence for increased dosage?},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2025},
  doi = {10.5588/ijtld.24.0465}
}
Kostenlos starten →